

Intended for healthcare professionals

●Rapid response to:

## Editorials

# Mass testing for covid-19 in the UK

BMJ 2020; 371 doi: <https://doi.org/10.1136/bmj.m4436> (Published 16 November 2020) Cite this as: BMJ 2020;371:m4436

## Linked Opinion

Screening the healthy population for covid-19 is of unknown value, but is being introduced nationwide

## Read our latest coverage of the coronavirus outbreak

- [Article](#)
- [Related content](#)
- [Article metrics](#)
- [Rapid responses](#)
- [Response](#)

## Rapid Response:

### Evidence of asymptomatic spread is insufficient to justify mass testing for Covid-19

#### Cookies and privacy

I Accept

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

Show Purp

#### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

#### List of Partners (vendors)

asymptomatic transmission is a genuine risk. Given the harmful collateral effects of such policies, precautionary principle should result in a very high evidential bar for asymptomatic transmission being set. However, the only word which can be used to describe the quality of evidence for this is woeful.

It is important to carefully distinguish purely asymptomatic (individuals who never develop any symptoms) from pre-symptomatic transmission (where individuals do eventually develop symptoms). To the extent that the latter phenomenon - which has in fact happened only very rarely - is deemed worthy of public health action, appropriate strategies to manage it (in the absence of significant asymptomatic transmission) would be entirely different and much less disruptive than those actually adopted.

Many early studies which purported to demonstrate the phenomenon of asymptomatic transmission were from China, yet the fact that Chinese studies are only published following government approval must bring into question their reliability (1). Nevertheless, the high volume of these studies spawned significant salience of the issue within the medical community, and an assumption of the likelihood of asymptomatic transmission being an important contributory factor. There then followed a number of meta-analyses examining the issue of asymptomatic transmission which tended to aggregate and give equal weight to studies regardless of origin or quality. In this way, these meta-analyses, given undue credibility by their association with reputable universities, amplified minimal evidence of asymptomatic spread to an importance the data did not warrant.

As reported in a manuscript submitted to this journal and also to medRxiv on 16 Dec 2020 (the latter available for download shortly), we examined the papers most frequently cited in support of the existence of asymptomatic transmission. Even despite our criticisms of the sources of the data above, we did in fact find only 6 case reports of viral transmission by people who throughout remained asymptomatic, and this was to a total of 7 other individuals, however all of these were in studies with questionable methodology.

Moreover in all these studies, confirmation of “cases” was made via PCR testing without regard to the possibility that any of the cases found might be false positives. The case numbers found, are, in any event extremely small and certainly not sufficient to conclusively determine that asymptomatic transmission is a major component of spread.

It is also notable that, in what would seem to represent an abrupt volte face by the CCP, a further (presumably government-approved) study from China was recently published (2) which entirely

## Cookies and privacy

I Accept

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

Show Purp

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)

Clare Craig BM BCh FRCPath

Silver, Andrew, and David Cyranoski. 2020. "China Is Tightening Its Grip on Coronavirus Research." Nature 580 (7804): 439–40.

Cao, S., Gan, Y., Wang, C. et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun 11, 5917 (2020). <https://doi.org/10.1038/s41467-020-19802-w>

**Competing interests:** No competing interests

**16 December 2020**

Jonathan H W Engler

Biotech Entrepreneur and Medical Doctor

Dr Clare Craig

N/A

Manchester and London

[@jengleruk](#) [@clarecraigpath](#)

## Cookies and privacy

I Accept

We and our partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Cookie policy](#)

Show Purp

### We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement, audience insights and product development, Use precise geolocation data, Actively scan device characteristics for identification

### List of Partners (vendors)